Sign In

Cade BioInformant

BioInformant.com, World's Largest Publisher of Stem Cell Industry News - Real Estate Investor - PatriotHoldings.com - CadeHildreth.com - Crypto

Cade Hildreth is a prominent figure in the stem cell industry and a successful entrepreneur. As the Founder and President of BioInformant.com, Cade has established the first and only market research firm specializing in the stem cell industry.12 BioInformant has become the world's largest publisher of stem cell industry news, attracting nearly one million readers per year.2

Professional Background

Cade founded BioInformant in 2006 and has since become a leading authority on stem cell market trends.1 With 16 years of experience, Cade is frequently sought after as a media expert on stem cells, having been interviewed by prestigious publications such as the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.12

Education and Achievements

Cade's educational background is impressive:

  • Bachelor of Science in Biology & Chemistry from Dartmouth College and Smith College1
  • Master of Science in Biochemistry & Molecular Biology with a specialization in BioInformatics & Biotechnology from Georgetown University, where Cade was Valedictorian12

Athletic Career

Beyond the business world, Cade has had a notable athletic career:

  • Former USA Rugby Player, training at the Olympic Training Center in Chula Vista, CA1
  • Represented the USA 7s Rugby Team in national and international competitions1
  • Competed with elite squads from New Zealand and Australia1
  • Named "International Rugby Player of the Year"1
  • Represented the USA in the 2015 FIT Touch Rugby World Cup in Australia1

Other Ventures

Cade is also involved in other business ventures:

  • Board Member and Advisor for Patriot Holdings, a commercial real estate private equity company12
  • Founder of CadeHildreth.com, a website focusing on personal finance, investing, and fitness, attracting over 2 million readers per year2

Personal

Cade identifies as LGBTQ+ and is passionate about lifestyle optimization.2 They have founded 7-figure businesses, scaled websites to millions of views, acquired a portfolio of income-producing real estate assets, and played rugby worldwide.2

In summary, Cade Hildreth is a multifaceted individual who has achieved success in business, academia, and athletics, while also being an advocate for the LGBTQ+ community and a thought leader in various fields.

Highlights

Jun 21 · linkedin

Trailhead Biosystems Puts iPSCs on a New Path - https://lnkd.in/g9p_wBWZ

Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research.

In 2007, Cleveland Clinic recruited Jan to apply his world-class expertise to two novel areas: regenerative medicine, and cell therapy for diabetes. The Cleveland Clinic continues to be ranked among the finest health care systems in the world, and Jan found himself surrounded by preeminent physicians, wishing to make an impact as a developmental biologist upon patient care.

Jensen then found himself faced with the opportunity to solve the problem of connecting lab knowledge to the exam room and operating table. In response, Jan founded Trailhead Biosystems to shift paradigms in both drug development and cell-based therapies. In addition to recently moving in to their new 12,000 sq ft facility, Trailhead recently launched their first remarkable product: iPSC-derived Oligodendrocytes.

Read more at: https://lnkd.in/g9p_wBWZ

#regenerativemedicine #celltherapy #ipsc

Jun 19 · linkedin

A Multi-Version Medicinal Technology System, Part II - https://lnkd.in/ebgsdFAk

With scientific results dismally challenging to replicate properly across disciplines, scientists, technologists, or investors with intact survival instincts cannot be naïve. No matter how gruff it sounds, a healthy respect for due diligence and fiduciary responsibility demands that good people ask, “Where’s the beef!?” at any time.

In Part I of this article, we first heard about “MSC 2.0,” 17 which is the second generation of mesenchymal stem/stromal cell (MSC) cellular technology. Like T cells, MSCs are a raw primary cellular source that irrigates multiple branches of downstream clinical applications that intermingle with other technologies.

Although one potentially promising use of “v2.0” involves cell-cultured and/or cruelty-free meat (aka “clean meat”), 76 we aim to inform you here that MSC 2.0 now supports other—more near-term—ventures of direct benefit to human health.

Read more at: https://lnkd.in/ebgsdFAk

#msc #stemcell #medicaltechnology

Related Questions

What inspired Cade Hildreth to start BioInformant.com?
How did Cade's rugby career influence his entrepreneurial ventures?
What are some key achievements of BioInformant.com under Cade's leadership?
How does Cade balance his roles as a CEO and a real estate investor?
What are the main focus areas of Patriot Holdings?
Cade BioInformant
Cade BioInformant, photo 1
Cade BioInformant, photo 2
Add to my network

Location

Washington DC-Baltimore Area